tert-butyl N-[(2S,3R)-3-hydroxy-4-[[4-(hydroxymethyl)phenyl]sulfonyl-(2-methylpropyl)amino]-1-phenylbutan-2-yl]carbamate | 910909-96-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl N-[(2S,3R)-3-hydroxy-4-[[4-(hydroxymethyl)phenyl]sulfonyl-(2-methylpropyl)amino]-1-phenylbutan-2-yl]carbamate
• CAS: 910909-96-5
• 化学式: C₂₆H₃₈N₂O₆S
• 分子量: 506.664
• InChiKey: YMDFDNLESFHFKS-BJKOFHAPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  35
• 可旋转键数：
  13
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  125
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  tert-butyl N-[(2S,3R)-3-hydroxy-4-[[4-(hydroxymethyl)phenyl]sulfonyl-(2-methylpropyl)amino]-1-phenylbutan-2-yl]carbamate 在 三乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 生成 (3aS,4S,7aR)-hexahydro-2H-furo[2,3-b]pyran-4-yl-(2S,3R)-3-hydroxy-4-(4-(hydroxymethyl)-N-isobutylphenylsulfonamido)-1-phenylbutan-2-yl carbamate
  参考文献：
  名称：

  Design and Synthesis of Potent HIV-1 Protease Inhibitors Incorporating Hexahydrofuropyranol-Derived High Affinity P₂ Ligands: Structure−Activity Studies and Biological Evaluation

  摘要：

  The design, synthesis, and evaluation of a new series of hexahydrofuropyranol-derived HIV-1 protease inhibitors are described. We have designed a stereochemically defined hexahydrofuropyranol-derived urethane as the P2-ligand. The current ligand is designed based upon the X-ray structure of la-bound HIV-1 protease. The synthesis of (3aS,4S,7aR)-hexahydro-2H-furo[2,3-b]pyran-4-ol, (-)-7, was carried out in optically active form. Incorporation of this ligand provided inhibitor 35a, which has shown excellent enzyme inhibitory activity and antiviral potency. Our structure activity studies have indicated that the stereochemistry and the position of oxygens in the ligand are important to the observed potency of the inhibitor. Inhibitor 35a has maintained excellent potency against multidrug-resistant HIV-1 variants. An active site model of 35a was created based upon the X-ray structure of 1b-bound HIV-1 protease. The model offers molecular insights regarding ligand-binding site interactions of the hexahydrofuropyranol-derived novel P2-ligand.

  DOI：

  10.1021/jm1012787
• 作为产物：
  描述：

  乙酰氧基-(4-氯磺酰基苯基)乙酸甲酯 在 4-二甲氨基吡啶 、 sodium tetrahydroborate 、 potassium carbonate 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 4.58h， 生成 tert-butyl N-[(2S,3R)-3-hydroxy-4-[[4-(hydroxymethyl)phenyl]sulfonyl-(2-methylpropyl)amino]-1-phenylbutan-2-yl]carbamate
  参考文献：
  名称：

  新型HIV-1蛋白酶抑制剂抗药性的基于结构的设计。

  摘要：

  描述了基于结构的设计和新型HIV蛋白酶抑制剂的合成。这些抑制剂经过专门设计，可与HIV蛋白酶活性位点的主链相互作用，以抵抗耐药性。抑制剂3具有极强的酶抑制和抗病毒效力。此外，该抑制剂对包括多种多重PI耐药性临床菌株在内的多种HIV都具有令人印象深刻的效力。抑制剂将立体化学定义的5-六氢环戊[b]呋喃基氨基甲酸酯作为P2-配体掺入（R）-（羟乙基氨基）磺酰胺等排物中。光学活性的（3aS，5R，6aR）-5-羟基-六氢环戊[b]呋喃是通过乙酰基胆碱酯酶的酶促不对称二乙酸双酯，自由基环化和路易斯酸催化的异头还原反应制备的。抑制剂3结合的HIV-1蛋白酶的蛋白质-配体X射线晶体结构（分辨率为1.35 A）显示，HIV蛋白酶活性位点具有广泛的相互作用，包括与骨架的强氢键相互作用。这种设计策略可能会导致可以抗药性的新型抑制剂。

  DOI：

  10.1021/jm060561m

文献信息

• Design and synthesis of potent HIV-1 protease inhibitors with ( S )-tetrahydrofuran-tertiary amine-acetamide as P2−ligand: Structure−activity studies and biological evaluation
  作者：Xiaoguang Bai、Zhiheng Yang、Mei Zhu、Biao Dong、Lei Zhou、Guoning Zhang、Juxian Wang、Yucheng Wang

  DOI：10.1016/j.ejmech.2017.05.024

  日期：2017.9

  The design, synthesis, and SAR study of a new series of HIV-1 protease inhibitors incorporating stereochemically defined tetrahydrofuran-tertiary amine-acetamide P2-ligand are described. Various substituent effects on the tertiary amine P2-ligand and phenylsulfonamide P2′-ligand were investigated to maximize the ligand-binding site interactions in the protease active site. Most of inhibitors displayed

  设计，合成和SAR研究的新系列的HIV-1蛋白酶抑制剂掺入立体化学定义的四氢呋喃-叔胺-乙酰胺P2-配体。研究了对叔胺P2-配体和苯磺酰胺P2'-配体的各种取代基作用，以使蛋白酶活性位点中的配体-结合位点相互作用最大化。大多数抑制剂表现出低纳摩尔至亚纳摩尔的抑制能力。抑制剂20E含有Ñ（ -小号-四氢呋喃） - ñ - （2-甲氧基乙基）乙酰胺，P2配体与4- methoxylphenylsulfonamide作为P2'-配体显示最有效的酶的抑制活性（IC沿50  = 0.35 1nM）和显着低的细胞毒性（CC 50 = 305μM）。
• C-3 SUBSTITUTED BICYCLOOCTANE BASED HIV PROTEASE INHIBITORS
  申请人：Ghosh Arun K.

  公开号：US20140148508A1

  公开（公告）日：2014-05-29

  C3-functionalized-cyclopentanyltetrahydrofuranyl carbamates that inhibit HIV proteolytic enzymes and processes for preparing the compounds are described. Compositions comprising the disclosed compound and methods of using the compounds and/or compositions for treating patients infected with HIV are also described.

  本文描述了抑制HIV蛋白酶酶和过程的C3-官能化环戊基四氢呋喃基氨基甲酸酯。还描述了包含所述化合物的组合物以及使用该化合物和/或组合物治疗HIV感染患者的方法。
• Structure-Based Design, Synthesis, and Structure−Activity Relationship Studies of HIV-1 Protease Inhibitors Incorporating Phenyloxazolidinones
  作者：Akbar Ali、G. S. Kiran Kumar Reddy、Madhavi N. L. Nalam、Saima Ghafoor Anjum、Hong Cao、Celia A. Schiffer、Tariq M. Rana

  DOI：10.1021/jm1008743

  日期：2010.11.11

  A series of new HIV-1 protease inhibitors with the hydroxyethylamine core and different phenyloxazolidinone P2 ligands were designed and synthesized. Variation of phenyl substitutions at the P2 and P2' moieties significantly affected the binding affinity and antiviral potency of the inhibitors. In general, compounds with 2- and 4-substituted phenyloxazolidinones at P2 exhibited lower binding affinities than 3-substituted analogues. Crystal structure analyses of ligand-enzyme complexes revealed different binding modes for 2- and 3-substituted P2 moieties in the protease S2 binding pocket, which may explain their different binding affinities. Several compounds with 3-substituted P2 moieties demonstrated picomolar binding affinity and low nanomolar antiviral potency against patient-derived viruses from HIV-1 clades A, B, and C, and most retained potency against drug-resistant viruses. Further optimization of these compounds using structure-based design may lead to the development of novel protease inhibitors with improved activity against drug-resistant strains of HIV-1.
• METHODS AND COMPOSITIONS FOR TREATING HIV INFECTIONS
  申请人：Ghosh Arun K.

  公开号：US20100113582A1

  公开（公告）日：2010-05-06

  Described herein are compounds and compositions that are useful in the treatment of HIV, AIDS, and AIDS-related diseases. In addition, compounds are described herein that are capable of inhibiting the dimerization of HIV proteases.
• US9309213B2
  申请人：——

  公开号：US9309213B2

  公开（公告）日：2016-04-12